What is the proposed benefit of treating Cannabinoid Hyperemesis Syndrome (CHS) with Droperidol over other antiemetics?
In a retrospective review of Emergency Department Records of 76 cases of CHS, those treated with droperidol had a significantly lower length of stay as compared with those patients treated with other antiemetics. (Lee C et al. The utility of droperidol in the treatment of cannabinoid hyperemesis syndrome, Clinical Toxicology 2019; 57:9, 773-777, DOI: 10.1080/15563650.2018.1564324)
Posted in Question Of The Day